SAS (Scandinavian Airlines) Improves Customer Service and Cuts Costs with Scandit’s Barcode Scanning on Smartphones
9.12.2019 10:00:00 EET | Business Wire | Press release
Scandit, the leading enterprise technology platform for mobile computer vision and augmented reality (AR), today announced that SAS (Scandinavian Airlines System) has integrated its powerful scanning software into their new Ground Handling App for smartphones, to replace expensive built-in scanners and upgrade critical ground workflows.
The mobile app (developed by Stockholm-based Objective Solutions) brings new efficiency and cost savings to workflows using mobile scanning of boarding passes, passports, meal vouchers and baggage tags. SAS has deployed the Scandit-powered app to their three Scandinavian airport hubs: Stockholm Arlanda, Oslo Gardermoen, and Copenhagen Kastrup. A detailed case study about the integration is now available.
SAS carries more than 30 million passengers annually to 120 destinations on over 170 aircraft and is widely recognized as a pioneer in digital innovation for the air travel industry. The Ground Handling App is part of a global, digital infrastructure initiative to streamline and improve key operations and improve the travelling experience for their growing volume of passengers. In the first deployment, SAS employees were equipped with 700 Galaxy A8 devices, with further rollouts planned across SAS’ global operations.
The Scandit software was easily integrated into the SAS IT ecosystem. Customer-facing SAS employees use the mobile app from anywhere in the airport, for example at the boarding gate where agents are no longer tied to gate podiums. Passengers are benefiting from a faster, more personalized service and SAS has reduced costs compared to the dedicated scanners and infrastructure. Booking changes can also be done seamlessly with the mobile app and baggage handlers use it to record and track baggage.
“We chose Scandit for its quality and flexibility,” said Fredrik Buxfeldt, Head of Digital Operations IT at SAS. “In addition to barcode scanning and OCR (optical character recognition) in mobile apps, Scandit also enables barcode scanning in websites, so our employees can also use mobile scanning from a browser if they don’t have the mobile app loaded.”
“SAS has reaped the benefits of modernizing data capture workflows with enterprise-grade mobile scanning,” said Samuel Mueller, CEO of Scandit. “We are delighted to play a part in this mobile evolution to help SAS meet its goals for outstanding customer service and operational efficiency.”
Resources
- View the SAS case study: https://www.scandit.com/resources/case-studies/sas/
- Learn more about Scandit’s air travel solutions: https://www.scandit.com/industries/air-travel/
- Download Scandit’s report (Fly High, One Mobile Scan at a Time) to learn how to innovate air travel with mobile computer vision and augmented reality: https://www.scandit.com/resources/whitepapers/fly-high-air-travel/
- Watch this video to see Scandit’s air travel solutions in action: https://www.scandit.com/resources/videos/air-travel-innovation-with-mobile-computer-vision/
- View Scandit’s press kit: https://www.scandit.com/press/
About Scandit
Scandit enables enterprises and consumers to change the way they interact with everyday objects and augment the physical world with real-time data captured by scanning barcodes and recognizing text, objects, and other visual identifiers using smartphones, tablets, wearables, drones, and robots.
Scandit’s mobile data capture platform is built on proprietary computer vision, augmented reality, and machine learning technologies. Companies in industries such as retail, transportation and logistics, manufacturing, and healthcare can use Scandit’s technology to create and power mobile apps for crucial enterprise workflows like search and find, shipping and receiving, inventory management, and proof of delivery.
Many of the world’s most innovative and successful companies are benefiting from Scandit’s enterprise-grade mobile data capture platform, including Alaska Airlines, FedEx, DHL, and PostNL.
For more information, visit https://www.scandit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191208005011/en/
Contact information
Brandon Watts
404-202-3476
brandon@wattsware.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom